Lunch Vendor Seminars

Therapeutic peptides represent one of the fastest‑growing classes of pharmaceutical drugs, bringing with them a distinct set of analytical and chromatographic challenges. Analytical teams are increasingly tasked with separating and characterizing process‑related impurities that may differ by only a few amino acids, closely related degradation products, and higher‑order species formed in peptide drug products in solution. 

Modern pharmaceutical and environmental applications demand separation strategies that perform across diverse compound classes. This presentation highlights a biphenyl stationary phase offering differentiated selectivity for challenging polyaromatic separations where conventional reversed-phase chemistries fall short.

The DAISOGEL Team will present our newest products and our approaches to solving your peptide(s) purification needs. We will highlight the science behind the new stationary phases and highlight their usefulness for peptide purification. Our manufacturing capacity for RP-HPLC silica is unmatched globally, as is our service.

Biotherapeutics are becoming increasingly diverse, placing greater demands on analytical platforms that support efficient development and regulatory readiness. Reversed-phase chromatography remains a versatile technique for applications ranging from oligonucleotide analysis to protein characterization and post-translational modification assessment.

High-performance liquid chromatography workflows depend heavily on efficient sample preparation, yet this stage is often the main source of delay. Solvent removal and sample concentration can slow throughput, especially when processing large batches or low concentration analytes.